Vol. 25 No. 5

Keeping investigators on the edge of their seats, new data from clinical trials evaluating ADCs continue to impress.

As genomic testing becomes ubiquitous in cancer care, some patients experience out-of-pocket costs that may affect oncologists’ genetic testing decisions.

The incorporation of immune checkpoint inhibitors has altered the treatment paradigm for endometrial cancer.

A deep dive into IL-15 targeted agents including N-803, those in the pipeline, and the fusion protein SAR445877 which Martin E. Gutierrez, MD, sheds light on.

Experts discuss updated findings from key clinical trials in hepatocellular carcinoma presented during the 2024 Gastrointestinal Cancers Symposium.

Two items in the medical world should send chills down the spines of those considering the possible financial future of oncology care in the United States.